AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus (Type 2) to be Presented at the American Diabetes Association's 72nd Scientific Sessions
Amarin Corporation plc (Nasdaq: AMRN) today announced that data from the AMR101 pivotal Phase 3 ANCHOR study will be presented in a poster at the American Diabetes Association's (ADA) 72nd Scientific Sessions at the Pennsylvania Convention Center in Philadelphia, Pennsylvania on June 9, 2012.
The poster, titled "Effects of AMR101 on Lipid and Inflammatory Parameters in Patients with Diabetes Mellitus-2 (Type 2) and Residual Elevated Triglycerides (200-500 mg/dL) on Statin Therapy at LDL-C Goal: The ANCHOR Study," will present an analysis of the effect on lipid and inflammatory parameters in patients with diabetes from Amarin's Phase 3 ANCHOR study. The ANCHOR study, a multicenter, placebo-controlled, randomized, double-blind, 12-week study, investigated AMR101 as a treatment for patients with high triglycerides (≥200 and <500 mg/dL) who were also on statin therapy for elevated low-density lipoprotein cholesterol. Of 702 total patients, 514 (73%) had diabetes mellitus-2.
This poster will be presented by Eliot A. Brinton M.D., FAHA, FNLA, Director of Atherometabolic Research, Utah Foundation for Biomedical Research, and President, Utah Lipid Center, in Salt Lake City. Dr. Brinton has served as President of the Pacific Lipid Association, is a founding board member of the National Lipid Association, and is Vice President of the American Board of Clinical Lipidology.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.